On February 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to umbralisib for the following indications: Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen Adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy. Read the FDA announcement. Read TG Therapeutics' announcement. Posted 2/8/2021
